LABA/LAMA combination

Indications

• maintenance treatment of COPD

Notes

• once-daily dry powder inhaler umeclidinium-vilanterol (Anoro) with decreased risk for a first moderate/severe COPD exacerbation with a vs. a metered-dose inhaler or soft mist inhaler (twice-daily glycopyrrolate-formoterol) or soft mist inhaler (tiotropium-olodaterol)
• the dry powder inhaler is environmentally friendly as it does not release fluorocarbons into the atmosphere.

More general terms

• pharmacologic combination

More specific terms

• fluticasone/vilanterol (Breo Ellipta)
• formoterol/glycopyrrolate (Bevespi Aerosphere)
• umeclidinium/vilanterol (Anoro Ellipta)

Components

• long-acting beta adrenergic receptor agonist (LABA)
• long-acting muscarinic receptor antagonist (LAMA)